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A drawback of gene therapy using adeno-associated 
virus (AAV) is the DNA packaging restriction of the viral 
capsid (<4.7 kb). Recent observations demonstrate over-
sized AAV genome transduction through an unknown 
mechanism. Herein, AAV production using an oversized 
reporter (6.2 kb) resulted in chloroform and DNase-resis-
tant particles harboring distinct “fragment” AAV (fAAV) 
genomes (5.0, 2.4, and 1.6 kb). Fractionation experi-
ments determined that only the larger “fragments” 
mediated transduction in vitro, and relatively efficient 
transduction was also demonstrated in the muscle, 
the eye, and the liver. In contrast with concatemeriza-
tion-dependent large-gene delivery by split AAV, fAAV 
transduction is independent of the catalytic subunit 
of DNA-dependent protein kinase (DNA-PKcs) in vitro 
and in vivo while disproportionately reliant on the DNA 
strand–annealing protein Rad51C. Importantly, fAAV’s 
unique dependence on DNA repair proteins, compared 
with intact AAV, strongly suggests that the majority of 
oversized AAV transduction is mediated by fragmented 
genomes. Although fAAV transduction is less efficient 
than intact AAV, it is enhanced fourfold in muscle and 
sevenfold in the retina compared with split AAV trans-
duction. Furthermore, fAAV carrying codon-optimized 
therapeutic dysferlin cDNA in a 7.5 kb expression cas-
sette restored dysferlin levels in a dystrophic model. Col-
lectively, oversized AAV genome transduction requires 
unique DNA repair pathways and offers an alternative, 
more efficient strategy for large-gene therapy.
Received 10 July 2012; accepted 27 July 2013; advance online  
publication 17 September 2013. doi:10.1038/mt.2013.184
INTRODUCTION
Adeno-associated virus (AAV) is a small (25 nm) single-stranded 
DNA (ssDNA, 4.7 kb) virus routinely used as a viral vector for 
human gene therapy. Many genetic variants of AAV exist, which 
allow transduction of a wide range of species and specific types of 
human tissues. AAV vectors (rAAV) carry only the 145-nucleo-
tide inverted terminal repeats (ITRs) and have contributed signifi-
cantly to the field of gene transfer, with >70 clinical trials initiated 
for a spectrum of genetic diseases.1,2 Among the many favorable 
attributes of rAAV, the fact that the AAV capsid is among the 
smallest described, imposes a DNA-packaging limitation (<5 kb) 
that has restricted its widespread application. This size constraint 
has traditionally rendered rAAV deficient for gene addition 
approaches requiring large transgenic cDNA, such as in hemo-
philia A, cystic fibrosis, and several types of muscular dystrophies, 
including dysferlinopathy.
rAAV cellular uptake relies on receptor-mediated endocy-
tosis and culminates in the presence of ssDNA within the host 
nucleus.3,4 There, the palindromic T-shaped ITR is extended by 
host-catalyzed second-strand synthesis in a manner independent 
of the cell cycle phase or cell division. The now-linear duplex DNA 
molecule is capable of transcription/transgene production and pri-
marily persists as a double-strand episome. Previous work using 
circularization-dependent single-stranded rAAV demonstrated 
that intramolecular circularization of the linear duplexed trans-
genic DNA occurs rapidly and is, initially, the primary persistent 
form of rAAV transgenic DNA.5 To a lesser extent, intermolecular 
linkages of rAAV genomes occur and increase in prevalence over 
time to form larger concatemers. Both of these processes, rAAV 
circularization and concatemer formation, are carried out by host 
DNA repair proteins representative of the major canonical path-
ways, homologous recombination (HR), and nonhomologous end 
joining (NHEJ).5–9 Previous reports have demonstrated that the 
ITRs are “recombinogenic” and play a role in circularization/con-
catemerization because they are bound and processed by effectors 
of both HR and NHEJ.6,10 Work from the Nakai lab has implicated 
two proteins involved in NHEJ, DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) and Artemis, for ITR processing, 
which were found necessary for concatemer formation in vivo.11 
In another study using dividing cells, ITR-induced HR was dem-
onstrated by the ability to tether distinct rAAV genomes using 
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a DNA oligonucleotide, which also acted as a repair template to 
induce intermolecular recombination.10 Additionally, the ITRs 
have been implicated in p53 activation, subsequent cell cycle 
arrest, and apoptosis in cells deficient for an “intact” DNA dam-
age response.12,13
To overcome the DNA-packaging limitation of AAV vectors, 
creative strategies based on the mechanistic understanding of 
genome processing have demonstrated large-gene transduction. 
Perhaps the most efficient approach is the use of split AAV (also 
called trans-splicing) vectors, which rely on cotransduction of dis-
tinct (and defined) AAV genomes in which vector “A” contains a 
promoter, coding sequence, and splice donor site, whereas vector 
“B” has a splice acceptor site and the remaining coding sequence 
followed by a poly-A tail.14–16 Cotransduction by these genomes 
will sometimes result in a desired concatemerization event, cre-
ating a functional cassette that is larger than the AAV capsid’s 
packaging capacity. This split vector context has been reported to 
occur in vitro and in vivo; however, the success of this approach 
is limited by the orientation of intermolecular concatemerization 
and the preferred tendency for AAV genomes to form circular 
monomers.10,14,15
Even though rAAV transduction was initially thought to be 
limited by its small packaging capacity (thus creating the need for 
split AAV vectors), several reports have recently described aspects 
of “oversized” gene transduction.17–24 This collective work sug-
gests that viral genome (vg) packaging initiates from the 3′ end 
of ssDNA molecules of both polarities until the capsid reaches its 
capacity.18 At that point, the external 5′ end of the large genome 
is truncated by an unknown process.18–21 To explain this phenom-
enon, the current theory states that 5′-end single-strand anneal-
ing of opposite polarity genome “fragments” is followed by 3′ 
palindrome-mediated extension to construct transgenic DNA 
that is larger than the capacity of a single particle.19 This “frag-
ment AAV” (fAAV) genome reassembly model is primarily based 
on the absence of observable large genomes using Southern blot-
ting.18–20,23,24 These reports contrast with an earlier observation, also 
relying on Southern blotting, which maintains that the AAV5 cap-
sid can package genomes up to 8.9 kb.17 Adding to the controversy, 
a recent report again failed to observe large AAV genomes (>5 kb) 
and concluded that fAAV transduction in muscle is mediated by 
HR.24 However, in that report, no direct evidence demonstrating 
a role for HR was provided. Furthermore, that hypothesis remains 
at odds with the canonical understanding that HR is restricted to 
dividing cells and the earlier report demonstrating packaged large 
AAV genomes (≈9 kb).17,24 Although the transduction mechanism 
of oversized AAV genomes remains uncertain, this approach has 
proven therapeutic in (i) mouse models of Stargardt syndrome 
and dysferlinopathy and (ii) a canine model of hemophilia A.17,23,24 
Nonetheless, the void of molecular understanding describing the 
mechanism of AAV large-gene reconstruction limits the possibil-
ity of these novel vectors contributing to the clinical arena due to 
potential safety concerns (i.e., fragmented vectors yielding frag-
mented proteins).
In this work, we characterized fAAV vectors at several levels: 
(i) the packaged genome; (ii) the integrity of the “full” rAAV cap-
sids; (iii) the transduction efficiency of different-sized fragments; 
(iv) the relative transduction efficiency of intact AAV in multiple 
tissues; (v) a quantitative comparison of fAAV and split AAV in 
cultured cells, skeletal muscle, and the retina; and (vi) the exten-
sion of this technology to an optimized dysferlin cDNA transgene 
cassette in a dystrophic mouse model. In addition, we demonstrate 
that fAAV transduction relies on a unique DNA repair mechanism 
compared with either intact or split AAV vectors. Our genetic 
analyses demonstrate the following: (i) intact vector transduction 
relies on Rad51C and XRCC3 while being independent of DNA-
PKcs; (ii) fAAV vector transduction disproportionately requires 
Rad51C and XRCC3 to a relatively lesser extent while being DNA-
PKcs independent; and (iii) split AAV requires Rad51C, XRCC3, 
and DNA-PKcs. The collective genetic analyses offer a character-
ized panel of repair-dependent transducing reporters, allowing 
investigations of the host DNA damage response in vitro and in 
vivo. Furthermore, the results demonstrate that the fAAV vectors 
are more efficient for large-gene delivery than traditional split 
AAV in cell culture, skeletal muscle, and retina. This work sug-
gests that >90% of fAAV transduction is mediated by fragmented 
AAV genomes and not by unobserved packaged large genomes, 
which has been debated in the literature.17–20 Collectively, fAAV 
represents an emerging strategy for the treatment of genetic dis-
eases requiring large-gene delivery.
RESULTS
Characterization of 6.2-kb fragment AAV 
preparations
Previous work has demonstrated the ability of rAAV vectors to 
mediate large-gene (>5 kb) transduction using a novel vector for-
mat, wherein the capsid is packaged with a 5′-truncated ssDNA 
genome (termed fragment AAV or fAAV).18–20,23,24 To character-
ize fAAV at a variety of levels, including its relative transduction 
efficiency compared with other AAV vector formats, we attempted 
to generate an rAAV vector packaged with a 6.2-kb genome. First, 
a plasmid vector was generated by inserting a 2.3-kb region of 
“stuffer” DNA into an intronic region of our standard ITR-flanked 
chick beta actin (CBA)-luciferase cassette (Figure 1a). Transfection 
experiments in human 293 cells demonstrated that this stuffer DNA 
did not affect luciferase activity when compared with the parental 
intact plasmid control (data not shown; (DNS)). Next, we generated 
a viral preparation of rAAV2-6.2 kb using a standard triple trans-
fection protocol followed by cesium chloride gradient purification 
(twenty 0.5-ml fractions were obtained).25 Samples of fractions 
1–15 (refractive index: 1.385–1.367) were dialyzed and treated with 
DNase to remove any “unprotected” DNA, followed by the addi-
tion of ethylenediamine tetraacetic acid to terminate the reaction. 
Then, the capsids were degraded, and the packaged genomes were 
denatured and electrophoresed on an alkaline gel. Southern blot 
detection demonstrated packaging of a single DNA species at ≈5 kb 
with less dense gradient fractions containing two additional smaller 
genomes at ≈2.4 and ≈1.6 kb (Figure 1b). In contrast, intact (3.9 kb) 
AAV vector analysis by Southern blotting of successive cesium chlo-
ride gradient fractions demonstrated the packaging of a single 3.9-
kb genomic species (Supplementary Figure S1, online). Notably, 
the different genome species observed with the larger AAV (6.2 kb) 
preparation did not vary when harvested from AAV2, AAV6, and 
AAV8 serotype capsids (Figure 1b, DNS). To determine whether 
the larger and smaller species were competent for transduction, we 
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first investigated viral titer by quantitative polymerase chain reac-
tion (qPCR; Figure 1c). Then, fractions 1–15 were normalized for 
titer and used for 293 cell infection at a ratio of 10,000 vg/cell and 
luciferase activity was assayed 2 days posttransduction (Figure 1d). 
Consistent with the hypothesis that only the larger DNA species 
would be able to reconstruct the 6.2-kb reporter, fractions 1–9 
mediated transduction, whereas the remaining fractions contain-
ing smaller species showed only slightly enhanced levels relative 
to the background (Figure 1d). Gradient fractions having refrac-
tive indexes of 1.381–1.376 g/cm3 or 1.381–1.371 g/cm3 (for in vitro 
or in vivo experiments, respectively) were then pooled to ensure 
a working titer, dialyzed, and used in the remainder of transduc-
tion experiments. The final titer of the in vivo fAAV preparation 
(1.381–1.371 g/cm3), as measured by quantitative Southern dot blot, 
was 1 × 1011 vg/15-cm plate, decreased ≈fivefold compared with the 
“intact” 3.9-kb control vector (Supplementary Figure S2a, online). 
However, this titer is within the standard range of AAV intact pre-
parations, depending on the genome size and sequence packaged 
(DNS).
Fragment AAV transduction in vitro
Next, fAAV transduction, using the viral preparation described 
above, was characterized under several conditions in human 293 
cells. We performed a single-strand DNase treatment of intact 
and fragment vectors before transduction to eliminate the pos-
sibility that the full-length 6.2-kb genome was externally associ-
ated with the AAV capsid, yet below the limit of Southern blot 
detection. First, we verified that ExoVII, a bidirectional single-
stranded nuclease, degrades ssDNA as reported by the manufac-
turer (DNS). Then, treatment of vector preparations using ExoVII 
resulted in a modest, yet statistically insignificant, decrease in 
the transduction efficiency of both vector types (Figure 2a). In 
additional experiments, the integrity of the AAV capsid was chal-
lenged by chloroform treatment, a condition known to dissoci-
ate improperly assembled capsids.26 Chloroform preincubation 
of both intact and fAAV vector types did not alter the transduc-
tion efficiency as measured by luciferase activity (Figure 2b). 
Collectively, these results suggest that fragment genomes of ≈5 kb 
are completely packaged in intact (chloroform-resistant) capsids 
Figure 1 Production and characterization of fragment AAV. (a) Illustration depicting the AAV plasmids that were used to generate “intact” and 
“fragment” AAV vectors. (b) Denaturing Southern blot of capsid-protected fragment AAV genomes from different cesium chloride gradient fractions 
following dialysis in 1× phoshate-buffered saline. A CBA-luciferase-radiolabeled probe (6.2 kb) corresponding to the region between the ITRs was 
used for detection. The boxed region represents DNA fragments of the indicated sizes. The refractive index (nD) of each fraction is depicted. (c) The 
quantity of viral genomes per milliliter was determined by quantitative polymerase chain reaction for the indicated cesium chloride gradient frac-
tions. (d) Transduction analysis of the indicated genome species derived from the indicated gradient fractions. This experiment was performed using 
a viral genome to cell ratio of 10,000 for transduction of 293 cells. Luciferase activity was determined 48 hours posttransduction and normalized to 
the total protein recovered.
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and mediate AAV large-gene transduction of a 6.2-kb transgenic 
cassette (Figures 1b and 2a,b). Next, the relative transduction 
efficiency of the fAAV–luciferase reporter preparation, compared 
with the intact 3.9-kb control, was investigated at different mul-
tiplicities of infection (MOIs; vg/cell) in a kinetic manner. At an 
MOI of 5,000, fAAV transduction was decreased ≈25-fold for 
luciferase activity compared with that at similar MOI of intact 
AAV in 293 cells (Supplementary Figure S2b, online). The kinet-
ics of fAAV expression were nearly identical to those of intact 
AAV as this transduction deficit was observed as early as 10 hour 
following virus administration and was maintained during the 
following 70-hour period (Supplementary Figure S2b, online). 
In addition, fAAV transduction demonstrated a standard satura-
tion curve following transduction of 293 cells at escalating MOIs 
(Supplementary Figure S2c, online).
These experiments using the 6.2-kb luciferase reporter dem-
onstrate the ability of rAAV to mediate large-gene transduction. 
To specifically eliminate DNA sequence and size concerns that 
could be unique to the fAAV–luciferase reporter (Figure 1), fAAV 
transduction was also attempted using a larger gene expression 
cassette under the control of the cytomegalovirus (CMV) pro-
moter. First, the 6.24-kb dysferlin coding sequence was optimized 
(Opt) for mouse/human codon usage and to eliminate the major-
ity of alternative open reading frames (GenScript; Figure  2c). 
Next, dysferlin abundance from wild type (WT) or Opt-dysf 
cDNA was evaluated by western blot following transfection in 
vitro (Supplementary Figure S3a, online), which was then nor-
malized to plasmid copy number abundance (Supplementary 
Figure S3b, online). The data demonstrate that the amount of 
dysferlin produced from either the WT or Opt-dysf cDNA was 
not significantly different in 293 cells or in mouse skeletal muscle 
(Supplementary Figure S3, online, DNS). However, because Opt-
dysf contains less alternative open reading frames, which could 
result in unwanted immunological complications,27 we generated 
fAAV CMV-Opt-dysf (7.5 kb) in capsids 2 and 6 for in vitro and 
skeletal muscle transduction, respectively (Figure 2c). Again, no 
DNA species >5 kb were observed by Southern blot analysis in 
either preparation (DNS). Then, the ability of fAAV (7.5 kb) to 
mediate Opt-dysf transduction in 293 cells was demonstrated by 
western blotting (MOI of 10,000; Figure 2d). In addition, fAAV6 
Opt-dysf was administered by intramuscular injection (5e10 vg) to 
the gastrocnemius muscle (N = 3) of the BlaJ Dysferlin-deficient 
mouse model (Figure 2e).28 Two weeks postinjection, total protein 
was recovered from the injected muscle and the dysferlin protein 
level was restored in tissue given AAV6 Opt-dysf but not in the 
control muscle injected with fAAV6–luciferase (Figure 2e). These 
collective experiments confirm the ability of fAAV to mediate the 
transduction using genomes of different sizes and sequences in 
vitro and in vivo (Figure 2).
Fragment AAV transduction in vivo
In previous work, the ability to use oversized vectors for gene 
delivery to the mouse eye, liver, and muscle was demonstrated 
(Figure 2e).17,23,24 However, the relative transduction efficiency 
in comparison with intact AAV (3.9 kb) was never evaluated. To 
answer this question in WT muscle, 5e10 vg of either intact or 
fAAV–luciferase (Figure 1a,b, Supplementary Figure S1, online) 
vectors were injected into the mouse gastrocnemius muscle (N 
= 4). For these experiments, the two vector types were produced 
using the AAV6 capsid, and Southern blot analysis of packaged 
DNA species demonstrated a similar profile to that observed with 
fAAV2–luciferase preparations (Figure 1b, DNS). As early as 3 
days postinjection, luciferase activity could be observed by live 
imaging in both treatment groups. At day 10 postinjection, the 
luciferase activity was quantitated using Igor Pro software and the 
results demonstrate that at this MOI, a 3.5-fold deficit for fAAV 
transduction, compared with the value determined for intact vec-
tor, existed (Figure 3a,c). The relative luciferase values for both 
vectors were maintained for >6 months in WT mouse muscle 
(DNS).
Our previous report demonstrated that liver transduction 
using fAAV–factorVIII (5.8 kb) corrected the bleeding phenotype 
Figure 2 Characterization of fragment AAV transduction in vitro. 
Fragment and intact AAV vectors were used for transduction follow-
ing enzymatic or chemical treatment at 5e2 vector genomes per cell. 
The intact (3.9 kb) and fragment (6.2 kb) vectors were pretreated with 
either exonuclease VII (ExoVII) or chloroform (CHCl3) for 1 hour before 
293 cell administration, respectively (a,b). Luciferase activity was deter-
mined 24 hours posttransduction. (c) A schematic illustration depict-
ing the AAV plasmid used to generate fragment AAV–Opt–dysferlin. (d) 
Fragment AAV2–Opt–dysferlin transduction of 293 cells, along with cells 
treated with a plasmid containing a CMV–Opt–Dysf expression cassette, 
analyzed by western blot demonstrating the 237-kDa Dysferlin protein. 
(e) Fragment AAV–Opt–dysferlin was injected in to the hindlimb of the 
BlaJ dysferlin–deficient mouse model (N = 3). One month after injec-
tion of 5e10 viral genomes, total protein was extracted and analyzed for 
Dysferlin protein by western blotting. AAV2–Opt–dysferlin transduction 
of 293 cells was used as a positive control, whereas BlaJ muscle injected 
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of the hemophilia A dog model.23 However, the relative trans-
duction efficiency in the liver, compared with intact AAV, was 
not investigated, which is important for translation of fAAV 
into the clinic, especially considering the lower production titers 
(Supplementary Figure S1, online). Therefore, fAAV–luciferase 
or the intact control, packaged in AAV8 capsid, was adminis-
tered intravenously to 8-week-old WT mice (N = 3). Twelve days 
following administration of 1 × 1011 vg, luciferase activity in the 
mouse liver was quantitated. Under these conditions, fAAV was 
clearly capable of liver transduction, albeit at a level 25-fold less 
than that of intact AAV8 vector (Figure 3b,c). As quantitative 
live imaging of the liver following systemic vector injection may 
also tally expression from neighboring tissues, an in vitro analy-
sis of luciferase activity was performed. Mice of a separate cohort 
(N = 3) were injected intravenously with 1 × 1011 vg of intact or 
fragment AAV8–luciferase vectors and equivalent liver samples 
were harvested 15 days postinjection. After tissue lysis, luciferase 
activity was measured in vitro and normalized to the amount of 
recovered protein. Similar to the value obtained by live imaging, 
a 37-fold decrease in transduction efficiency was noted for fAAV 
compared with intact vectors (Supplementary Figure S4, online).
In addition to the liver and skeletal muscle, the transduction 
efficiency of fAAV was also directly investigated in the eye fol-
lowing subretinal injections (N = 3). Again, intact AAV–luciferase, 
which does not require intracellular gene reconstruction, served 
as a relative control. For these experiments, AAV2 was used at a 
dose of 5e8 vg for both vector types. Twelve days postinjection, 
luciferase activity from the total eye was quantitated, and the 
results demonstrate that fAAV transduction decreased about 
eightfold compared with intact AAV in this isolated tissue com-
partment (Figure 3c).
Comparison of AAV large-gene transduction 
strategies
The finding that fAAV is capable of large-gene (6.2 and 7.5 kb) 
transduction in several mouse tissues expands the utility of AAV 
vectors for therapeutic applications requiring transgenic DNA 
>5 kb. However, additional AAV vector strategies for large-gene 
delivery have been described and of these vector formats, split 
AAV (also termed trans-splicing) has been deemed the most effi-
cient.14 To determine the relative transduction efficiency of fAAV 
compared with that of split AAV, we generated split luciferase 
Figure 3 Characterization of fragment AAV transduction in vivo. (a). Either intact or fragment AAV6–CBA–luciferase vectors (5e10 viral genomes) 
were injected into wild-type mouse gastrocnemius skeletal muscle at the indicated dose (N = 4/treatment). The depicted image was taken 10 days 
postinjection. (b) The indicated AAV8 vectors were injected intravenously into wild-type mice (N = 3) at a dose of 1 × 1011 viral genomes. The depicted 
image was taken 12 days postinjection. The expanded inset labeled “longer exposure” refers to an increased integration time allowing visualization 
in the picture. (c) Quantitation of the luciferase values determined in the distinct data sets in a and b presented as fold change derived by the aver-
age value determined for the intact vector divided by the average value determined for the fragment vector. In addition, the fold change for values 
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vectors that are genetically similar (Figure 4a). The split AAV 
approach relies on the cotransduction of two distinct vectors: 
(i) vector A contains the CBA promoter, followed by a partial 
luciferase coding sequence and a splice donor site; and (ii) vec-
tor B has a splice acceptor signal, the remaining luciferase coding 
sequence, and a poly-A tail (Figure 4a). Transduction by vector 
A or B alone did not result in luciferase activity (DNS); however, 
a particular intermolecular linkage event of the genomes of vec-
tors A and B following cotransduction resulted in a functional 
luciferase cassette (Figure 4). AAV large-gene transduction was 
initially compared in vitro using fAAV2 and split AAV2 vectors. 
The results demonstrated that at the same final MOI (fAAV or 
split vectors A and B), fAAV is significantly enhanced for trans-
duction, compared with split AAV, in dividing C2C12 myoblasts 
and myotubules (Figure 4b). Transduction of three different 
types of cells (hamster, mouse, and human) demonstrated that 
this enhancement was conserved across multiple species in cell 
culture, suggesting there is no cell type–specific discrepancy in 
the measured activities (Figure 4b, Supplementary Figure S5, 
online). We also compared the efficiency of large-gene transduc-
tion by split AAV and fAAV in vivo following intramuscular injec-
tions (N = 3). Similar luciferase activities were noted for both split 
and fAAV transduction when administered a high dose of vector, 
possibly representing saturation of our upper limit of detection 
(Figure 4c). However, when the administered dose was decreased 
tenfold, a significant increase in luciferase activity (fourfold) was 
noted in muscle-given fAAV relative to the value determined for 
split AAV (Figure 4c).
In addition, the transduction efficiencies of split and fAAV2 
was evaluated in the eye following subretinal injections (5e8 vg; 
N = 3). Although live imaging of luciferase activity is possible fol-
lowing intact AAV vector transduction at this dose, the sensitivity 
of detection using the repair-dependent vectors was not (DNS). 
Therefore, 1 month postinjection, total eye lysate was prepared 
and luciferase activity was determined in vitro and normalized to 
total recovered protein. From this analysis, fAAV demonstrated a 
sevenfold enhancement in luciferase activity compared with that 
of split AAV (Figure 4d).
Mechanistic evaluation of AAV large-gene 
transduction strategies in vitro
Thus far, AAV-mediated transduction of oversized cassettes has 
been primarily assumed to be mediated by AAV fragments based 
on the absence of large packaged genomes observed by Southern 
blotting (Figure 1b).18–20,23,24 However, it is possible that DNase-
resistant genomes are packaged17 and mediate transduction yet are 
below the sensitivity of detection (Figure 1b). To define the sensi-
tivity of detection of the Southern blotting protocol used herein, we 
diluted the intact AAV–luciferase (3.9 kb) vector beyond our detec-
tion and compared transduction efficiencies in 293 cells. The intact 
vector genome was detected on alkaline Southern gels in the range 
of 50 ng–50 pg using a 5-day exposure to film (Figure 5a). A viral 
genome amount of 25 pg defined the lower limit of our Southern 
detection; however, transduction by this amount of packaged AAV 
genomes resulted in luciferase activity 2-logs higher than that of 
the vehicle control (Figure 5b). An additional fivefold dilution to 
5 pg of viral DNA still maintained transduction >tenfold higher 
than that of background (Figure 5). This result undermines the 
assumption that fAAV transduction is actually mediated by frag-
ments because it is quite clear that viral DNA species not observed 
by alkaline Southern blots mediate efficient transduction.18–20,23,24
Considering the concerns of detection sensitivity using 
Southern analysis, a genetic approach was used to investigate 
the DNA repair mechanism (if one exists) responsible for the 
large-transgene reconstruction initially by using well-established 
Chinese hamster ovary (CHO) mutant cell lines.5 For these 
experiments, we used a V3 DNA-PKcs mutant that is defective 
for NHEJ.29,30 We also investigated rAAV transduction in irs3 
and irs1SF cells, which are reported deficient in HR due to unde-
tectable levels of Rad51C and XRCC3, respectively.31,32 For these 
experiments, AAV2 large-gene transduction was determined by 
luciferase activity estimation 2 days postadministration in the 
mutant strains and compared with the value determined for the 
Figure 4 Efficiencies of split and fragment AAV vector transduction. 
(a) An illustration depicting our split AAV reporter, which consists of two 
distinct vectors: (i) vector A contains a promoter, followed by partial 
luciferase coding sequence and a splice donor sequence and (ii) vec-
tor B has a splice acceptor sequence, the remaining luciferase coding 
sequence, and a polyA tail (intron derived from the β-globin intron II 
sequence). (b) Transduction of dividing and nondividing mouse C2C12 
myoblasts and myotubules by the indicated type of AAV2 vector sys-
tem at a total dose of 1 × 105 viral genomes per cell. Luciferase activity 
was quantitated 72 hour following vector administration, and the fold 
change between the values derived from dividing and arrested cells is 
presented. (c) The indicated rAAV6 vector type was injected through 
the intramuscular route at the indicated viral genome (vg) dose (N = 3). 
Luciferase activity was quantitated 20 days postinjection. (d) The indi-
cated rAAV2 vector type was injected into the subretinal space (N = 3) 
and luciferase activity was determined as described in the text. For split 
AAV vectors, the final dosing refers to split vector A + split vector B. In all 
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WT parental lines.5 As the intact vector does not require DNA 
repair, other than second-strand synthesis, for luciferase expres-
sion, it serves as our reassembly-independent control vector. In 
the absence of DNA-PKcs, intact and fAAV transduction was not 
significantly altered (Figure 6a). In contrast, split AAV transduc-
tion decreased ninefold in these cells, indicating a role for DNA-
PKcs in split-vector large-gene reconstruction (Figure 6a). The 
results obtained from intact vector transduction of the Rad51C-
deficient cells demonstrate a nearly tenfold decrease in transduc-
tion, indicating a reassembly-independent role for Rad51C in 
AAV vector transduction (Figure 6a). A similar decrease in trans-
duction in the Rad51C-mutant cells was noted for split-vector 
transduction. In contrast, fAAV transduction was disproportion-
ately affected, demonstrating a 50-fold decrease in the absence 
of Rad51C (Figure 6a). Additionally, rAAV vector transduction 
was investigated in CHO cells containing the irs1SF mutation, 
which is complemented by the RecA/Rad51-related HR protein 
XRCC3. Similar to the results obtained in the Rad51c-deficient 
line, intact and split vector transduction decreased ~tenfold com-
pared with the appropriate control strains.5 However, fAAV trans-
duction was affected to a lesser degree, <threefold in the XRCC3 
background (Figure 6a). These collective results provide genetic 
evidence indicating that the DNA repair factors that contribute 
to intact, split, and fAAV vector transduction are distinct: (i) split 
and intact AAV vector transduction relies to a similar extent on 
Rad51C and XRCC3; (ii) split transduction requires DNA-PKcs 
while intact and fAAV does not; and (iii) fAAV transduction dis-
proportionately requires Rad51C, although the transduction defi-
cit for intact and split vectors observed in the XRCC3 background 
is not observed (Figure 6a).
Figure 5 Southern blot sensitivity and AAV transduction. (a) The 
indicated amount of packaged viral genomes (AAV–CBA–luciferase 3.9 kb 
“intact”) was analyzed by alkaline Southern blot using the luciferase cod-
ing sequence as a probe. (b) Intact vector transduction of 293 cells using 
intact particles harboring the indicated amount of viral genomes.
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Figure 6 rAAV vector transduction dependency on DNA repair pro-
teins. (a) The indicated AAV–luciferase vector type was used for trans-
duction in the appropriate WT, Rad51C-deficient (irs3), XRCC3-deficient 
(irs1SF), and DNA-PKcs-deficient (V3-3) CHO cells as described in text. 
Luciferase activity was determined 24 hours after virus administration, 
and statistical significance was determined a student t test followed by 
Bonferroni correction to account for the multiple comparisons. (b) The 
indicated rAAV reporter context was used for transduction in the increas-
ing presence of a DNA-PK inhibitor II (µmol/l) as described in the text. 
Again, luciferase activity was assayed 24 hours after adding AAV, and 
the results are presented as the fold change in activity (drug/vehicle). 
(c) The indicated rAAV6 vector type was administered to WT or DNA-
PKcs-deficient mice by muscle injection (N = 3) at a dose of 5e10 viral 
genomes. Luciferase activity was determined 20 days postinjection and 
is presented as the fold change by dividing the value determined for WT 
mice with that determined in the mutant mice. In (b,c) a student t test 
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To further confirm the canonical NHEJ independence of 
fAAV transduction, the influence of DNA-PK inhibitor II was 
investigated in HeLa cells. Consistent with decreased split AAV 
transduction in the DNA-PKcs–deficient cells, both of the tested 
inhibitor concentrations (1 and 10 µmol/l) decreased luciferase 
activity following split AAV transduction (Figure 6b). In contrast, 
intact and fAAV transduction were not significantly altered at 
either concentration of the DNA–PK inhibitor (Figure 6b).
Mechanistic evaluation of AAV large-gene 
transduction strategies in vivo
Results from genetic and pharmacological analyses demonstrate 
a differing role for DNA-PKcs in AAV large-gene transduction; 
split AAV is DNA-PKcs dependent, whereas fAAV is Rad51C 
dependent and completely independent of DNA-PKcs. To observe 
whether this pattern holds true in vivo, AAV large-gene transduc-
tion was investigated in mice deficient for DNA-PKcs. For this 
experiment, 5e10 vg of either vector type packaged in AAV6 were 
administered directly to mouse skeletal muscle (N = 3). Twenty 
days postinjection, the transduction efficiency was determined by 
luciferase activity. Consistent with the results obtained in vitro, 
split AAV vectors showed tenfold decreased transduction in the 
DNA-PKcs background, whereas the transduction efficiency of 
fAAV and intact AAV was not significantly altered (Figure 6c).
DISCUSSION
Thus far, therapeutic applications of rAAV-mediated gene therapy 
have met with encouraging success for genetic disorders, such 
as Leber congenital amaurosis and hemophilia B. These initial 
human results have increased the popularity of AAV for DNA 
delivery in the clinic and also present additional challenges, most 
of which can be addressed by vector enhancements that allow 
efficient transduction at lower doses. It was traditionally thought 
that rAAV was of little use for the treatment of genetic diseases 
requiring transgenic DNA >5 kb, a restriction imposed by its small 
viral capsid. However, recent work evaluating an earlier claim that 
AAV5 can package 8.9-kb genomes collectively concluded using 
Southern detection that no genomes, using vectors with differ-
ent sequences, >5 kb were packaged.18–20,23,24 Instead, truncated 
large genome fragments were thought to be packaged, which 
mediated large-gene transduction at an unknown efficiency.22 
Mechanistic evidence supporting this theory is yet to be shown, 
although, recent work based on Southern blotting concluded that 
AAV5-based oversized gene transduction in muscle fibers relies 
on HR, again suggesting that this process relies on fragmented 
AAV genomes.24 However, no direct evidence was provided dem-
onstrating host-mediated HR of the presumed fragmented AAV 
genomes, and furthermore, this conclusion contradicts the long-
held understanding that HR is restricted to dividing cells.24 The 
work herein provides genetic evidence demonstrating that the 
majority of oversized AAV vector transduction is mediated by 
fAAV genomes that show a disproportionate dependence on a 
unique DNA repair pathway (Figures 1,6).
Our analysis of the 6.2-kb AAV–luciferase vector preparations 
demonstrated that DNA genome species of ≈5 kb were packaged, 
as determined by Southern analysis (Figure 1b). Despite this 
result, the detection sensitivity of Southern blotting is a concern 
(Figure 5), and hence it remains a formal possibility that larger 
genomes could be packaged and perhaps mediate transduction as 
previously reported.17,33 Subsequent data rebuking the initial claim 
of large-gene packaging did not conclusively rule out this possibil-
ity, and neither does the work herein; however, our genetic analy-
ses suggest that the majority of oversized transduction is mediated 
by AAV genome fragments (Figure 6).18–20,23,24 Specifically, the 
majority of the observed fAAV reporter activity requires Rad51C, 
a DNA strand–transfer protein involved in annealing during HR, 
at a level more than tenfold that observed for intact AAV (Figure 
6a). Conceptually, as both small and large intact AAV genomes 
require second-strand synthesis and transcriptional activation 
(intact and fAAV both have an identical promoter), it is not 
immediately apparent how proteins involved in HR would dif-
ferentially act on these templates that differ only by 2.5 kb (sup-
porting the notion that fAAV transduction is mediated by DNA 
fragments). In addition, we have performed plasmid transfections 
in CHO lines using the constructs used to generate the intact and 
fAAV vectors. Importantly, no fAAV construct–specific effect was 
noted in the Rad51C or XRCC3 backgrounds, demonstrating that 
there is no transcription-specific effect of these repair proteins on 
the 3.9- or 6.2-kb cassette expression (DNS). Thus, the genetic 
data argue that Rad51C influences AAV transduction of intact, 
fAAV, and split vectors while an additional statistically significant 
effect (more than tenfold) is exerted on fAAV at a level other than 
transcription, presumably genome reconstruction. Therefore, our 
data imply that at least the majority of fAAV transduction herein 
is not mediated by large intact undetected genomes, but rather 
by genomes requiring DNA repair mechanisms other than those 
required by intact genomes (Figures 1b,5,6). However, fAAV 
transduction in the Rad51C-deficient cell line was not completely 
eliminated (Figure 6a). This result is not immediately understood 
but could be explained by an unknown Rad51C redundant func-
tion in this cell line, a Rad51C-independent pathway for fAAV 
transduction, or by the existence of intact AAV genomes that 
are not visible by Southern blotting yet mediate transduction 
(Figure 1d).
The preference to package discrete ssDNA species in the capsid 
is not understood, and we observed approximate sizes of 1.6, 2.4, 
and 5 kb while attempting to package a 6.2-kb genome (Figure 1). 
Interestingly, only gradient fraction containing the ≈5-kb DNA 
species demonstrated significant transduction. Current genome-
sequencing efforts are yet to yield results. As the truncation 
mechanism is unknown, it remains possible that it occurs by 
either intracellular or extracellular pathways (during purifica-
tion). Experiments testing these hypotheses are also underway. 
Currently, analyses of the replicative forms of our 6.2-kb luciferase 
reporter and the 7.5-kb dysf cassette suggest that genome frag-
mentation does not occur during replication, which is consistent 
with an earlier report (DNS).33 With reference to particle integrity, 
chloroform tolerance suggests that fAAV capsids are intact, unlike 
misformed AAV capsids that were capable of large-DNA trans-
fer in cell culture (Figure 2b).26 The results of the ExoVII ssDNA 
digestion before fAAV transduction also support normal capsid 
integrity (Figure 2a).
In terms of transduction efficiency, fAAV showed decreased 
efficiency compared with intact AAV, anywhere from threefold to 
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50-fold depending on the transduced cell type/tissue and method 
of administration (Figures 2,3, Supplementary Figure S2b,c, 
online). An indirect correlation was noted between the size of 
the transduced compartment and the fold difference observed 
between fAAV and intact vectors (i.e., less than fivefold in isolated 
muscle following injections and >25-fold in the liver following 
intravenous injection). This observation is perhaps rationalized by 
requirement of multiple genome fragments for fAAV transduc-
tion although a single intact AAV genome can theoretically result 
in luciferase activity.
To determine the most efficient AAV large-gene delivery 
approach, a quantitative comparison was performed between 
fAAV and split AAV vectors. Our analyses in skeletal muscle are 
consistent with the results obtained in a variety of cell lines that 
demonstrate that fAAV is more efficient than the traditional split 
vector approach (Figure 4, Supplementary Figure S5, online). In 
addition, a comparison of large-gene transduction by these vectors 
in the mouse retina demonstrated a sevenfold increase in trans-
duction efficiency for fAAV compared with split AAV (Figure 4d). 
However, it should be understood that these vectors, by nature, 
are not genetically identical. Specifically, split AAV vectors require 
a particular orientation of ITR-mediated concatemerization and 
transcription through a processed DNA hairpin, both of which 
inhibit the efficiency of this approach.10,34 The obtained results 
demonstrating that fAAV transduction is more efficient than split 
vectors makes sense theoretically as opposite strand polarities 
would be “directed” to the correct orientation by the overlapping 
and complementary truncated 5′ genome ends.18 In the case of 
split vectors, reconstruction of the desired transgene product only 
occurs with a likelihood of one in six, as concatemerization events 
are directed by homologous ITRs that flank all intact transduced 
genomes.10 Furthermore, AAV genomes prefer self-circulariza-
tion.5 This speculation probably rationalizes the results in which 
the enhanced transduction by fAAV compared with split AAV 
was markedly increased in cell culture, skeletal muscle, and retina 
(Figure 4, Supplementary Figure S3, online). However, a recent 
report using “dual hybrid” trans-splicing AAV vectors, which con-
tain additional “recombinogenic” sequences within the introns of 
split vectors A and B, demonstrated enhanced transduction, yet 
they were not tested herein.16
Our analysis of the genetic reconstruction of large genes medi-
ated by AAV delivery suggested that the repair pathway depen-
dence of intact, fragment, and split vectors is overlapping, yet 
distinct, in dividing cells (Figure 6): (i) intact vector transduction 
relies on Rad51C and XRCC3 while being independent of DNA-
PKcs; (ii) fAAV vector transduction disproportionately requires 
Rad51C, and XRCC3 to a relatively lesser extent, while being 
DNA-PKcs independent; and (iii) split AAV requires Rad51C, 
XRCC3, and DNA-PKcs. This DNA repair requirement for split 
AAV genomes is consistent with previous reports that demon-
strate split AAV genomes can be assembled by both HR and NHEJ 
DNA repair pathways.6,10,11 The results also demonstrate that 
although both intact and split AAV vectors are decreased in the 
XRCC3 background to a similar degree, there is significantly less 
of an effect on fAAV (Figure 6a). Thus, fAAV is highly dependent 
on Rad51C, and transduction is slightly enhanced in the absence 
of XRCC3 (compared with intact or split vector transduction) 
(Figure 6a). As Rad51C is a ssDNA-binding protein that pro-
motes strand annealing during repair of double strand breaks, 
it seems logical that it may function on the overlapping and 
complementary free ssDNA ends of fAAV genomes (Figure 6a). 
Rad51C has been shown to be unique among the Rad51 paralog 
proteins in that it relocalizes to the nucleus after DNA damage, 
and it has been reported to transport Rad51 into the nucleus.35 
In addition, Rad51C interacts with three paralog protein com-
plexes involved in HR: (i) Rad51C/XRCC3, (ii) Rad51B/C, and 
(iii) Rad51-B-C-D/XRCC2.36–38 Given the diverse roles of Rad51C 
in HR, it perhaps is not surprising that fAAV transduction is dis-
proportionately reduced, compared with intact and split vectors, 
in the deficient background. Furthermore, the modestly elevated 
levels of transduction in the XRCC3-deficient cells could suggest 
XRCC3-mediated inhibition of Rad51C-mediated fAAV genome 
reconstruction and, to a lesser extent, AAV transduction in gen-
eral (Figure 6). Studies elucidating the precise mechanism of 
fAAV transduction are under investigation. Interestingly, fAAV 
transduction showed dependency on Rad51C in dividing cell 
culture; however, transduction was noted in contexts that are 
deficient for HR, including arrested cells and differentiated tissue 
(Figures 4,6). In these contexts, it is possible that noncanonical 
end-joining pathways reconstruct fAAV, and experiments testing 
this hypothesis are in progress. Canonical NHEJ, which relies on 
DNA-PKcs and largely mediates split AAV transduction, does not 
appear to influence fAAV, or intact AAV, transduction in vitro and 
in vivo under the tested conditions (Figure 6). In contrast, AAV 
vector concatemerization, split AAV, relies on the DNA-PKcs 
pathway, which has been previously reported.11 These experiments 
demonstrate the viral versatility of AAV vectors to use different 
host DNA repair pathways for natural persistence, which can then 
be exploited for diverse mechanistic and therapeutic applications 
(Figures 2c–d,6).17,23,24
In addition to elucidation of fragment vectors at the levels of 
transgenic DNA reconstruction and relative transduction effi-
ciency, we extended our fAAV analysis to a CMV–Opt–dysf cas-
sette in the skeletal muscle of the BlaJ Dysferlin-deficient mouse.28 
Importantly, this extends our fAAV investigations to an additional 
promoter and transgene of a larger size (total cassette is of 7.5 kb; 
Figure 2c–e). Given previous immunological concerns with alter-
nate open reading frames, dysferlin cDNA optimization, which 
changes the nucleotide codon sequence while preserving the 
native amino acid usage, was performed by GenScript.27 Despite 
several reports in which codon optimization resulted in increased 
protein abundance, we did not observe this scenario for Opt–dysf 
cDNA in vitro (Supplementary Figure S3, online).39,40 However, 
fAAV–Opt–dysf restored Dysferlin protein in deficient BlaJ muscle 
at a viral dose of 5e10 vg via intramuscular injection (Figure 2e). 
Previous experiments have demonstrated that restoration of 
dysferlin in a dysferlin-deficient mouse can partially relieve the 
dystrophic phenotypes.24,28,41 However, using a transgenic mouse 
approach, it was also observed that overexpression of this protein 
in muscle results in a progressive myopathy.42 Investigations are 
underway to define the efficacy levels of dysferlin and to regulate 
its cellular abundance following gene transfer experiments.
Of particular importance for therapeutic applications is the 
observation that the overall titer of fAAV is consistently fivefold to 
Molecular Therapy vol. 21 no. 12 dec. 2013 2213
© The American Society of Gene & Cell Therapy
Oversized AAV Transduction
tenfold lower than intact AAV and, perhaps more troublesome, that 
it is contaminated by DNA species that do not mediate transduc-
tion (Figure 1, Supplementary Figure S1, online). In the past, we 
have noticed that different purification methods often favor certain 
vector genome species, and different column chromatographies are 
under investigation for fAAV particle isolation. Specifically, it is of 
interest to exclude the smaller fAAV genome fragments that were 
not transduction competent but contributed to our determination 
of overall vector titer (Figure 1b–d; Supplementary Figure  S2, 
online). Thus, the effective titer of our fAAV preparations used 
herein are likely to be decreased more than tenfold compared with 
intact AAV and the efficiencies of transduction, if anything, are 
underestimates.
Collectively, the work herein is the first report providing 
mechanistic evidence that the majority of fAAV large-gene trans-
duction is, indeed, mediated by genomes requiring a unique host 
DNA repair process. This is an important finding considering the 
assumptions based on the poor sensitivity of Southern blot detec-
tion (Figure 5) in light of a report that states that the AAV5 cap-
sid, specifically, can package up to 8.9 kb.17–20,23,24 Given the cell/
tissue targets used herein, we did not investigate oversized genome 
packaging in AAV5; however, AAV2, 6, and 8 capsids packaged 
DNA fragments of similar size. From a therapeutic standpoint, 
fAAV appears to be an efficient method for large-gene transduc-
tion given our head-to-head comparison with split AAV in vitro, 
in skeletal muscle, and in the retina. However, clinical translation 
concerns exist for fAAV applications, including the following: (i) 
the low production titer (Supplementary Figure S2a, online), (ii) 
the contamination of preparations by nontransducing DNA spe-
cies (Figure 1b–d), and (iii) the potential production of aberrant 
genomes/proteins from nonconservative AAV genome repair. An 
additional concern following fAAV transduction is that by nature 
(as it is reported to have no ITR sequence at the 5′ end), it may be 
enhanced for host chromosome integration.18 However, prelimi-
nary studies in dividing cell culture suggest that the integration 
frequency is not enhanced relative to that of intact AAV vectors 
(DNS). Despite these concerns, fAAV transduction has already 
demonstrated preclinical success by alleviating symptoms of 
Stargardt syndrome and dysferlinopathy in mouse models.16,24 In 
addition, our group has demonstrated the ability to overcome the 
scalable production barriers for fAAV, by curing dogs with hemo-
philia A using a 5.8-kb therapeutic cassette.23 Therefore, from both 
mechanistic and therapeutic standpoints, fAAV represents a novel 
reagent to study the in vivo DNA damage response and exploit it 
for the generation of enhanced diseased therapies.
MATERIALS AND METHODS
Maintenance of cells. Most cells were grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% heat-inactivated fetal bovine serum and 
1× Penn/Strep (DMEM+, Sigma). These cells include the lines CHO-
K1, CHO AA8, CHO V79-4, CHO irs3, CHO irsf1, CHO V3-3, C2C12, 
HeLa, and HEK 293s.5,43,44 These cells were maintained at 37 °C in a 5% 
CO2 humidified incubator. C2C12 cells were differentiated into nondivid-
ing myotubules by growth in DMEM containing 2% fetal bovine serum 
for 2–3 weeks and myotubules were verified using microscopy (DNS). 
DNA-PK inhibitor II (SantaCruz, SantaCruz, CA) was used to treat cells at 
1 and 10 µmol/l concentrations (in DMSO). For the comparison of protein 
production by weight or codon-optimized dysferlin cDNA, HEK293T cells 
were cultured in DMEM GlutaMax-I medium (Invitrogen) with 10% fetal 
bovine serum (Gibco, Invitrogen, Carlsbad, CA) and 10 μg/ml gentami-
cin (Gibco, Invitrogen) at 37 °C with 10% CO2. For transfection, 1.0E+07 
cells were plated on a 10-cm dish (40–50% confluence), cultured for 24 
hour, and transfected with 6 µg of plasmid DNA using Fugene (Roche, 
Indianapolis, IN) according to the recommended instruction. Three days 
after transfection, cells were harvested after trypsinization and collected 
into two tubes, for the western blot and the qPCR analysis.
Plasmid constructs. To generate the oversized AAV ITR plasmid 
(Figure  1a), the AvrII/SpeI fragment of pCINEO (Promega, Madison, 
WI) was cloned into the XbaI site of pTR2-CBA-luc by blunt ligation. The 
AAV genome size is 6.209 kb. For split luciferase vector construction, a PCR 
product was generated using a plasmid containing the β-globin intron II 
inserted into luciferase cDNA construct (RJS) as template. Terminal SphI 
and ClaI sites were introduced and used for cloning into the “split A” back-
bone pTR2–CBA–luc (“intact” 3.9-kb plasmid vector). The split B vector 
was generated using PCR cloning (of the same template) and inserted into 
the KpnI/NotI site of pTR2–egfp (RJS). Primer sequences are available on 
request. For the ITR plasmid that contains the fragment, the optimized dys-
ferlin cDNA was cloned out of MH197 by XbaI and SphI digestions and 
inserted into the corresponding sites on pTR2–CMV–egfp. The comparison 
of expression of optimized dysferlin and wild form was performed using the 
following constructions: plasmid pCMV–eGFP_DysferlinFL_Isoforme8 
(GENETHON) and plasmid CMV–eGFP_Opt–Dysferlin. The plasmid 
pCMV–eGFP_pOptiDysferlin was constructed by inserting a fragment 
containing the cytomegalovirus (CMV) promoter and the eGFP coding 
sequence into the plasmid pOpt–Dysferlin, upstream of the optimized dys-
ferlin cDNA. Constructs were confirmed by DNA sequencing.
AAV production and characterization. All vectors used in this study were 
produced using a triple transfection protocol, followed by CsC1 gradient 
centrifugation and dialysis in 1× phosphate-buffered saline (PBS) solution 
as previously described.25 The pXR series plasmids 2, 6, and 8 were used 
to package genomes in capsids 2, 6, and 8, respectively. Final virus titer 
was determined after dialysis in 1× PBS by qPCR (described under qPCR 
analysis) and Southern dot blot, and the packaged species were analyzed 
by alkaline gel electrophoresis followed by Southern blotting.25 A plasmid 
cut fragment corresponding to the entire 3.9-kb intact luciferase genome 
was used as a template for P32-labeled probe synthesis by random primed 
labeling (Roche).
rAAV transduction. For experiments in vitro, 50,000 viable cells were 
seeded in a 24-well plate 24 hour before transduction. The next day, 
virus particles were added directly to the well at the dose described in 
the “Results.” At the indicated time points, cells were lysed directly in the 
well using a passive lysis buffer according to manufacturer’s recommenda-
tion. Luciferase activity was then determined using a Victor 2 luminom-
eter (Perkin Elmer, Waltham, MA) and normalized to total protein in the 
lysate determined by Pierce 660 nm protein assay reagent. All experiments 
were performed in triplicate on at least three different days, and the results 
are presented as averages of the experimental data. The ssDNA nuclease 
ExoVII (Epicentre) was used using the manufacturer’s conditions for the 
vector pretreatment experiment. The negative control in these experiments 
was treated identically, however, without the addition of ExoVII. For rAAV 
transduction in vivo, experiments were carried out with 6- to 8-week-old 
female BALB/c, BALB/c DNA-PKcs, or the B6 BlaJ (dysferlin-deficient) 
mice (Jackson Labs, Bar Harbor, ME), unless otherwise indicated. All 
mice were maintained and treated in accordance with National Institutes 
of Health guidelines and as approved by IACUC at UNC–Chapel Hill. All 
intramuscular injections were performed following intraperitoneal injec-
tion of 2.5% avertin (250–500 mg/kg) or transient anesthetization using 
2.5% isoflurane. Then the vector dose indicated in the text was injected 
directly into the muscle using a 30-gauge syringe in an equal volume of 80 
µl for the gastrocnemius. For intravenous injections, the tail vein was used 
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for virus or vehicle (in all cases, PBS) administration at the dose indicated 
in the results. For subretinal injection, a glass capillary pipette was used 
to pierce the sclera at the level of the limbus after the eye was dilated with 
tropicamide 1% (Falcon Pharmaceuticals, Abingdon, VA) and topical pro-
paracaine (0.5%, Falcon Pharmaceuticals) was given for local anesthesia. 
A glass cover slip was utilized to visualize the needle in the vitreous cavity, 
and the contralateral retina was pierced for entry into the subretinal space. 
Approximately 1 µl of virus or PBS was injected into the eye using a micro-
scope at the dose described in the text. A total of three eyes, in which injec-
tions were visible, considered equivalent, and without bleeding, were used 
for analysis. These injections were self-sealing and did not require sutures.
Animal imaging studies. Luciferase transgene expression in live animals 
was obtained using a Xenogen IVIS Lumina imaging system (Caliper 
Lifesciences, Hopkinton, MA). Mice were first anesthetized using 2.5% 
isoflurane in a gas chamber and then injected IP with excess d-luciferin 
(5 mg in PBS, Caliper). Five minutes after the injection, image analysis was 
carried out using the Living Image software (Caliper Lifesciences), and 
luciferase expression is reported in relative light units as described by man-
ufacturer. As shown in Figure 3, the light intensity scale can be adjusted for 
image presentation purposes, which is independent of the data analysis by 
the Living Image software.
In vitro luciferase assay for eye and liver transduction. WT mice (N = 
3) were injected with 1 × 1011 vg of intact or fragment AAV8 luciferase 
reporter vectors. At 15 days postinjection, an equivalent portion of the 
liver was harvested and analyzed for luciferase activity using standard con-
ditions. Luciferase activity was normalized to the total recovered protein 
as determined by a Bradford assay. Noninjected mice (N = 3) were used as 
negative controls (no virus). For the eye injections described above, lucif-
erase activity was determined (N = 3) 1 month postinjection in the total 
eye lysate. Luciferase activities were normalized to total recovered protein 
as described above.
Western blot analysis and immunoflourescence. Protein was extracted 
from transfected cells using cell lysis buffer (20 mmol/l Tris–HCl pH: 7.5, 
150 mmol/l NaCl, 2 mmol/l EGTA, 0.1% Triton, and Proteases Inhibitors 
(E-64, Merck and Complete, Mini, Roche))[Manufacturer query should 
be added here], and protein concentrations were determined by the BCA 
Protein Assay kit (Pierce). The lysates were loaded at 215 μg total protein 
per lane. Detection of Dysferlin was performed using standard Odyssey 
protocol, with primary specific monoclonal anti-Dysferlin antibody (NCL-
Hamlet-2, Novocastra) diluted 1:2,000. Blot was probed using the Odyssey 
secondary antibody DAM 800 diluted 1:5,000, scanned, and quantified 
using the Odyssey Application Software 2.1 (LI-COR). For in vivo west-
ern blot analysis (N = 3), total protein was recovered from the gastrocne-
mius muscle using the lysis solution M-PER (Pierce) and a TissueLyser 
LT (Qiagen, Redwood City, CA) as recommended by the manufacturers. 
Approximately 30 µg of total protein was separated on a NuPage 4–12% 
BisTris gel (Invitrogen) and transferred to a nitrocellulose membrane via 
i-Blot (Invitrogen). The NCL-Hamlet-2 antibody was used at 1:1,000 dilu-
tion overnight, and an anti-mouse IgG-horseradish peroxidase secondary 
antibody was used in conjunction with the Pierce West Pico chemilumi-
nescent detection kit.
qPCR analysis. DNA was extracted from transfected cells by DNeasy 
Blood and Tissues Kit (Qiagen), according to the manufacturer’s instruc-
tions, after homogenization with a Microtube Pellet Pestle Motor (Fisher 
Scientific, Waltham, MA). The quantity and quality of the isolated DNA 
was determined with NanoDrop ND 1000 (NanoDrop Technologies, 
Wilmington, DE). The primer pairs and Taqman probe used for enhanced 
green fluorescent protein (eGFP)-specific detection were as follows: 
614GFP. Forward: 5′-AGTCCGCCCTGAGCAAAGA-3′; 680GFP. 
Re verse: 5′-GCGGTCACGAACTCCAGC-3′; and 636GFP_Probe: 5′-CAA 
CGAGAAGCGCGATCACATGGTC-3′. The ubiquitous albumin protein 
was used to normalize the data across samples. Primers and probe 
used for albumin-specific detection were as follows: Alb. Forward: 
5′-GCTGTCATCTCTTGTGGGCTGT-3′; Alb. Reverse: 5′-ACTCATGGG 
AGCTGCTGGTTC-3′; and Alb.Probe: 5′-CCTGTCATGCCCACACAAA 
TCTCTCC-3′. The number of copies of eGFP and albumin in each sample 
was determined by a standard curve made by serial dilutions of a plasmid 
carrying the albumin–eGFP sequence.
For quantitation of the luciferase AAV preparations by qPCR 
using SYBR green staining, the following primers were used: 
Luciferase R: CCTTCGCTTCAAAAAATGGAAC, luciferase F: AAAA 
GCACTCTGATTGACAAATAC (5,105 and 1,093 bp from either ITR); 
SV40 polyA R: CCAGACATGATAAGATACATTGATGAGTT, SV40 
polyA F: AGCAATAGCATCACAAATTTCACAA (233 and 5,954 bp 
from either ITR).
Statistical analysis. Student’s t test was used to determine significant dif-
ferences. A value of P < 0.05 was considered significant and, in most cases, 
the P value is indicated in each figure.
SUPPLEMENTARY MATERIAL
Figure S1. Southern blot analysis of intact rAAV2 cesium chloride 
gradient fractions.
Figure S2. Fragment AAV production and transduction evaluation.
Figure S3. Comparison of wild type and optimized Dysferlin abun-
dance following transfection.
Figure S4. Transduction comparison of intact and fragment AAV vec-
tors in the liver.
Figure S5. Transduction comparison of the indicated AAV–CBA–lu-
ciferase vectors in: A) human 293 cells and B) Chinese hamster ovary 
cells (CHO).
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